CRL
Charles River Laboratories
Charles River Laboratories historical holders
total: 7
Polen Capital Management Charles River Laboratories transactions over time
- Total transactions:
- 12
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 7
- Held since:
- 2022 Q2
- Held for:
- 11 quarters
- Latest activity:
- 2025 Q1
Polen Capital Management has been an institutional investor in Charles River Laboratories (CRL) since 2022 Q2. According to 2026 Q1 report, Polen Capital Management doesn't hold any shares. The fund/company first acquired CRL in 2022 Q2, initially purchasing 4,685 shares. Since the initial investment, Polen Capital Management has made 11 more transactions in this position.
When did Polen Capital Management exit their CRL position?
Polen Capital Management no longer holds Charles River Laboratories (CRL). They sold off their entire position in 2025 Q1, closing out an investment that began in 2022 Q2.
When did Polen Capital Management first invest in CRL?
Polen Capital Management first invested in Charles River Laboratories (CRL) in 2022 Q2 at the reported quarter-end price of $213.87 per share, acquiring 4,685 shares in their initial purchase.
What is Polen Capital Management's average cost basis for CRL?
Based on historical transaction data, Polen Capital Management's estimated cost basis for Charles River Laboratories (CRL) is approximately $218.54 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $218.54
- Weighted AVG sell price:
- $191.75
CRL transactions history by Polen Capital Management
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$184.60
|
|
-100% (-4,248)
|
-0%
|
|
2024 Q4
|
0.00%
|
4,248
|
$184.60
|
$784,181
|
-22.82% (-1,256)
|
-0%
|
|
2024 Q3
|
0.00%
|
5,504
|
$196.97
|
$1,084,123
|
-3.69% (-211)
|
-0%
|
|
2024 Q2
|
0.00%
|
5,715
|
$206.58
|
$1,180,605
|
-5.69% (-345)
|
-0%
|
|
2024 Q1
|
0.00%
|
6,060
|
$270.95
|
$1,641,957
|
-4.24% (-268)
|
-0%
|
|
2023 Q4
|
0.00%
|
6,328
|
$236.40
|
$1,495,939
|
+26.43% (+1,323)
|
+0%
|
|
2023 Q3
|
0.00%
|
5,005
|
$195.98
|
$980,880
|
+1.01% (+50)
|
+0%
|
|
2023 Q2
|
0.00%
|
4,955
|
$210.25
|
$1,041,789
|
-9.40% (-514)
|
-0%
|
|
2023 Q1
|
0.00%
|
5,469
|
$201.82
|
$1,103,754
|
-3.85% (-219)
|
-0%
|
|
2022 Q4
|
0.00%
|
5,688
|
$217.90
|
$1,239,415
|
+22.32% (+1,038)
|
+0%
|
|
2022 Q3
|
0.00%
|
$196.77
|
-0.75% (-35)
|
|||
|
2022 Q2
|
0.00%
|
$213.87
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.